Articles tagged with Blood Cancer
A Mayo Clinic study found that people with monoclonal B-cell lymphocytosis (MBL) have a 92% elevated risk of developing melanoma. MBL is a precursor to chronic lymphocytic leukemia and also increases the risk of cancers originating in the lymphatic system and serious infections.
Scientists at Van Andel Institute and Icahn School of Medicine have developed a potent anti-cancer compound that inhibits cancer cell growth in MLL-rearranged leukemia. MS-41 effectively targets and degrades ENL, a protein essential to the progression of leukemia cells.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Infant leukemia with MLL gene rearrangements is resistant to glucocorticoids due to the production of NG2 protein. This leads to FLT3 activation and inactivation of the glucocorticoid receptor, rendering cells insensitive to treatment. The study provides new targets for drug development and immunotherapy.
The study found that 29% of patients experienced progression-free survival at five years and 40% achieved overall survival. However, important survivorship issues were identified, including nonrelapse mortality rates of 16.2%, with over half occurring beyond two years post-treatment.
Researchers identified genetic and metabolic characteristics of leukaemic stem cells, including a specific iron utilisation process that can be blocked to kill these cells without harming healthy ones. This breakthrough paves the way for new therapeutic strategies to combat leukemia.
Researchers at the Mayo Clinic Comprehensive Cancer Center discovered a new treatment approach that improved survival rates for patients with B-cell precursor leukemia by nearly 60%. The study found that adding blinatumomab to chemotherapy reduced the risk of leukemia recurrence and death.
A preclinical study suggests that knocking out CD5 on CAR T cells boosts their anti-tumor efficacy against various cancers, including solid tumors. The researchers found that CD5 deletion enhances the function of CAR T cells by reining in immune responses and increasing cancer-cell-killing activity.
A novel strategy using venetoclax and azacitidine demonstrates significant anti-cancer effect with mild toxicity for relapsed/refractory AML patients. The treatment showed markedly better survival rates after one year compared to a control group, with improved 'graft-versus-leukemia effects' via alterations of immune cells.
A new study published in PNAS reveals that cancer patients who receive hematopoietic cell transplants from donors with lower socioeconomic status experience reduced overall survival and increased transplant-related mortality. The research highlights the profound impact of social inequality on health outcomes, particularly in cancer care.
A new study predicts patient outcomes for blood cancer treatment using personalized simulations based on genomic sequencing data. The approach successfully identifies patients with varying prognoses across multiple datasets, providing robust predictions despite mutational heterogeneity.
Researchers at the University of Plymouth have discovered that administering a HDAC6 inhibitor prior to radiotherapy can inhibit cellular growth and increase cell death in meningioma samples. This promising approach could lead to improved treatment outcomes for malignant meningioma patients.
A phase II clinical trial found trametinib effective in treating pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML), with seven of ten patients alive after two years. The treatment showed antitumor activity and downregulated inflammatory signaling, offering hope for JMML patients and their families.
A large Stanford Medicine study has found that the risk of secondary blood cancers after CAR-T cell therapy is low, around 6.5% in three years. The therapy did not introduce lymphoma into patients with pre-existing cancer cells, which were already present at low levels.
A new detailed analysis of a patient's second cancer after receiving CAR-T therapy provides valuable guidance for clinicians. The study reveals that CAR-T related second cancers can occur, often with lymphomas, and highlights the need for early detection and management.
Researchers developed a nine-week, phone-delivered positive psychology program called PATH to improve psychological well-being in blood cancer patients. The intervention had promising effects on patient-reported outcomes, with high participation and completion rates.
Researchers at UC Davis Health discovered that mesalamine can replace good bacteria's work in fighting Candida albicans in the gut. The study found that mesalamine maintains a low oxygen environment that prevents fungal growth, reducing the risk of invasive candidiasis.
A new 'armored' form of CAR T cell therapy, developed by University of Pennsylvania researchers, has shown significant responses in patients whose cancers don't respond to current CAR T cell therapies. The three-day manufacturing process also shortens treatment time for aggressive, fast-growing cancers.
Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.
The FDA committee voted unanimously to approve minimal residual disease (MRD) as a new clinical endpoint for evaluating proposed drugs to treat multiple myeloma. A meta-analysis led by C. Ola Landgren shows a strong correlation between MRD and clinical outcomes in newly diagnosed and relapsed patients.
Scientists have discovered 17 new genes involved in clonal haematopoiesis, a process associated with ageing linked to increased risks of blood cancers. The findings highlight the clinical significance of these genes in driving mutant blood cell clones, offering new avenues for studying disease development and promoting healthier ageing.
Researchers at Goethe University Frankfurt have discovered thalidomide derivatives that target and degrade BCL-2, a protein essential for the survival of cancer cells. The derivatives bind to CRBN, reprogramming its binding surface to mark BCL-2 for degradation, ultimately leading to cell death.
A third Covid vaccine dose has been shown to improve defensive antibody responses in some clinically extremely vulnerable patients. The trial found that 90% of patients who received a booster dose developed significant antibodies, but more than half of those with low initial responses saw no improvement.
A new study published in JAMA Oncology highlights the importance of testing for measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) undergoing bone marrow transplants. The researchers found that detecting MRD can help predict cancer recurrence and improve patient outcomes.
A new genetic testing procedure identifies patients at high cardiovascular risk due to clonal haematopoiesis and carotid artery stenosis. This allows for early detection of increased mortality and a personalized cardiovascular risk profile, enabling therapy adaptation and prevention of atherosclerotic disease progression.
A novel combination of two existing drugs has been discovered to eradicate AML cancer cells in lab-based tests, offering hope for patients diagnosed annually with the disease. The treatment, pairing venetoclax with a STING agonist, showed high promise in AML samples driven by a mutated p53 protein, a type of AML generally harder to treat.
Researchers identified elevated MALAT1 levels in various blood cancers, correlating with adverse outcomes. MALAT1 promotes cancer cell proliferation, migration, invasion, and metastasis through multiple mechanisms.
Researchers have developed a urine-based test that detects pieces of DNA fragments released by head and neck tumors, providing a non-invasive alternative to traditional blood-based biomarker tests. The test has been shown to detect cancer recurrences far earlier than would typically happen based on clinical imaging.
Researchers highlight the role of post-transcriptional RNA modifications in AML pathogenesis, identifying m6A and m7G regulators as potential therapeutic targets. Targeted therapies, including selective inhibitors and Traditional Chinese Medicine compounds, show promise in promoting cell differentiation and reversing AML phenotypes.
Researchers used single-molecule microscopy and X-ray crystallography to discover that pathogenic JAK2 mutations utilize pseudokinase domain-mediated dimerization as a mechanism for activation. The study provides new insights into the molecular basis of JAK2 activation and its role in blood cancers.
Researchers at Johns Hopkins Kimmel Cancer Center have developed a novel antibody-drug conjugate (ADC) therapy that effectively kills T-cell cancers in mice with human T-cell tumors. The treatment targets TRBC1 protein expressed on the surface of cancer cells while preserving normal T cells.
Researchers developed a method using lipid nanoparticles to activate T cells and deliver genetic instructions in one step, simplifying the CAR T cell manufacturing process. This new approach reduces production time from 48 hours to 24 hours and increases accessibility to patients worldwide.
Researchers at RCSI have identified a new treatment option for multiple myeloma by combining venetoclax with 5-azacytidine. This combination shows enhanced efficacy across various patient samples and has the potential to expand treatment options for those resistant to standard care.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
Researchers identify mitochondrial priming as a key driver of multi-drug resistance in relapsed acute myeloid leukemia. A new technique called dynamic BH3 profiling reveals anti-cancer drugs capable of overcoming resistance.
A study published in Cell Stem Cell found that restricting iron levels in blood stem cells can reverse their decline and improve regenerative capacity. The researchers discovered that excess intracellular iron activates inflammation within HSCs, while restricted iron levels enable them to multiply and respond effectively.
The European LeukemiaNet has published two-part guidelines for adult acute lymphoblastic leukemia treatment, covering diagnostics, prognostic factors, response assessments, and comprehensive management. These recommendations are based on a decade of systematic work by European experts, improving the prognosis of adult patients with ALL.
A recent study published in JAMA Network Open found that vaccinated adults with hematologic cancers were at high risk of severe COVID-19, even after receiving treatment. The study included 6,122 patients and showed no significant decline in severe cases through mid-2022.
A phase 2 study by Mount Sinai-led researchers demonstrates rusfertide's ability to limit excess red blood cell production in patients with polycythemia vera, a rare and chronic blood cancer. The results suggest it could replace therapeutic phlebotomy, providing improved treatment options for patients.
A team of researchers from the University of Tokyo demonstrated that a drug, valemetostat, reduces tumor growth in blood cancer by targeting H3K27me3, a protein modification silencing tumor suppressor genes. The treatment restores expression of many tumor suppressor genes and sustains inhibiting tumor cell growth.
Researchers discovered genes encoding growth regulators normally not present in myeloid cells are expressed by leukaemic stem cells, allowing them to grow. Repurposed drugs targeting these receptors show promise in blocking stem cell growth and preventing disease relapse in specific types of AML.
Researchers discovered a link between single cancer cell mutations and clinical response to epigenetic therapy in myelodysplastic syndrome. Patients showing treatment benefits had decreased mutation counts in stem cells and immature granulocytes, suggesting early tumor elimination is key to therapy success.
A study published in Blood Advances found that combination therapies can significantly reduce blood pressure in patients taking ibrutinib. The research suggests that different drug combinations may be more effective depending on whether patients had high blood pressure before or developed it while taking the drug.
Researchers at the John Theurer Cancer Center have co-authored a study on oral decitabine-cedazuridine therapy, which is now shown to be pharmacologically and pharmacodynamically equivalent to its intravenous counterpart. This innovation has significant potential for patient benefit and improved comfort in cancer treatment.
A pilot study proposes a promising global genomic assay for diagnosing molecular subtypes in pediatric B-ALL, leading to more accurate diagnosis and targeted treatment options. RNA sequencing analysis accurately identified subtypes in all known cases and determined genetic subtype in 79% of previously unknown cases.
Researchers found decreased BMAd density and altered distribution profile in MGUS patients who developed MM, indicating early changes in bone marrow adipose tissue. These findings suggest the potential for timely interventions and personalized treatment strategies.
Researchers have identified a significant link between inherited genetic variants and the development of rare blood cancer, myeloproliferative neoplasms (MPNs). Inherited genetic variants can influence whether a spontaneous mutation increases the risk of developing MPN.
Researchers discuss reductive carboxylation of glutamine as a potential target in acute myeloid leukemia (AML), an aggressive cancer with poor patient outcomes. The approach aims to weaken tumor cell survival mechanisms, potentially leading to novel therapies and improved patient outcomes.
Researchers found that specific microbes in the gut reduce graft versus host disease after stem cell transplantation. Patients with low microbial metabolite risk index had better survival rates, fewer graft vs. host reactions, and reduced relapses.
A study published in Blood Advances found liso-cel to be a cost-effective treatment for r/r DLBCL, with a lower societal ICER of $68,212 per QALY. The treatment offered improved quality-adjusted life years and reduced lost productivity costs.
GFH009 inhibits tumor growth and induces apoptosis in various HHM-derived cell lines. The compound's mechanism of action involves rapid 'on-off' inhibition of CDK9, which exerts a proapoptotic effect on cancer cells.
A new study found that removing the RUNX1 transcription factor and its target gene can lead to a network collapse, causing cancer cell death in a type of aggressive leukemia. This breakthrough identifies specific protein targets for potential treatments.
A microbial sensor, Nod1, plays a crucial role in the development of blood stem cells. The discovery could lead to the creation of patient-derived blood stem cells, eliminating the need for bone marrow transplants and improving lives of leukemia, lymphoma, and anemia patients. Researchers are continuing to study the complex interaction...
Researchers investigated mechanisms of NK cell-mediated killing in various types of blood cancers, uncovering genes involved in sensitivity and resistance to NK cell therapies. The study aims to develop new personalized immunotherapies for improved cancer treatment outcomes.
A phase III trial has found that personalised treatment for chronic lymphocytic leukaemia (CLL) can improve survival and remission rates. The trial showed that individualising therapy based on regular blood tests significantly improved progression-free and overall survival in patients with previously untreated CLL.
A Phase I clinical trial of AT101, a new CAR T cell therapy targeting CD19 through a distinct binding mechanism, has shown a 100% complete response rate in patients with relapsed or refractory B cell non-Hodgkin's lymphoma. The treatment was found to be safe with manageable side effects and is expected to build upon the effectiveness o...
Researchers at University of Cincinnati Cancer Center present Phase 2 clinical trial results for a new BTK inhibitor treatment that offers potential for improved efficacy and safety in chronic lymphocytic leukemia. The study also explores the use of IRAK4 inhibitors to target acute myeloid leukemia cells, with promising results.
Researchers from the Mass General Cancer Center presented studies on psychiatric and substance use disorders as independent predictors of treatment response and outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia (AML) treated with Venetoclax Combinations. Additionally, a Phase 1 Study of CAR-T-ddBCMA for the...
Studies at single-cell resolution reveal significant tumor cell heterogeneity and an immune-evasive environment that contributes to treatment resistance in T follicular helper cell lymphomas. A novel marker, PLS3, is also identified as a key player in this process.
A recent study by Goethe University Frankfurt has identified a mechanism that could be a suitable starting point for developing novel drugs against leukemia cells. The researchers discovered that the mutated NPM1 gene variant drives pro-autophagic activity, enabling cancer cells to recycle their structures and meet their needs.